| 研究課題/領域番号 |
22K20989
|
|---|
| 研究種目 |
研究活動スタート支援
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
0907:口腔科学およびその関連分野
|
|---|
| 研究機関 | 大阪大学 |
|---|
研究代表者 |
|
|---|
| 研究期間 (年度) |
2022-08-31 – 2024-03-31
|
| 研究課題ステータス |
交付 (2022年度)
|
| 配分額 *注記 |
2,860千円 (直接経費: 2,200千円、間接経費: 660千円)
2023年度: 1,430千円 (直接経費: 1,100千円、間接経費: 330千円)
2022年度: 1,430千円 (直接経費: 1,100千円、間接経費: 330千円)
|
|---|
| キーワード | Scaffolds / Macrophages / Immunomodulation / Biomaterials / Tissue regeneration |
|---|
| 研究開始時の研究の概要 |
It is hypothesized that regulation of macrophage activity can be achieved by using biomaterials. In this research project, the macrophage response to polymeric scaffolds developed in our laboratory will be evaluated.
|
| 研究実績の概要 |
Our poly(lactic acid/caprolactone) copolymer (PLCL) technology was used to fabricate porous scaffolds of different sizes, from 200 um to 2.5 mm thickness. This achievement means that PLCL scaffolds can be adapted to numerous applications in tissue regeneration, and are not limited to bone regeneration as initially hypothesized in our proposal. Gas plasma treatment of PLCL scaffolds was performed, and new functional groups were detected by FTIR-spectroscopy. However, field emission SEM revealed different degrees of structural damage. Macrophages cultured on PLCL scaffolds showed a proliferation rate comparable to that of control materials; however, signs of scaffold degradation were observed by SEM, indicating that macrophages were engaged in the breakdown and phagocytosis of PLCL scaffold.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
We have established a modified method to fabricate PLCL porous scaffolds in various sizes. The PLCL scaffolds treated with gas plasma presented functional groups that can be used for loading bioactive molecules such as cytokines. Further evaluations of cytokine loaded PLCL can be performed within this fiscal year (2023). Overall, we believe that this research is progressing smoothly.
|
| 今後の研究の推進方策 |
Considering the different degrees of damage to the PLCL scaffold structure observed by field emission SEM, we plan to further optimize the parameters for gas plasma treatment and minimize the damage. Additionally, plasma treated scaffolds will be loaded with a reference protein (bovine serum albumin) or with an immunomodulatory cytokine (interleukin 4), for analyzing their release profile. Finally, phagocytic activity and cytokine release of macrophages cultured on PLCL scaffolds will be evaluated.
|
